Growmax Medicare - About the company
Growmax Medicare is an unfunded company based in India, founded in 2008. It operates as a Manufacturer of pharmaceutical formulations including cardiac, diabetic, and nutritional products. Growmax Medicare has not raised any funding yet. The company has 1830 active competitors, including 94 funded and 204 that have exited. Its top competitors include companies like AbbVie, Gilead and Amgen.
Company Details
Manufacturer of pharmaceutical formulations including cardiac, diabetic, and nutritional products. The business produces a wide range of medications spanning therapeutic areas such as gastrointestinal treatments, antibiotics, and antifungals. Operations involve the development of medicinal products that undergo testing to ensure compliance with standards. The entity supplies various pharmaceutical solutions for distribution to healthcare providers.
Key Metrics
Sign up to download Growmax Medicare's company profile
Growmax Medicare's funding and investors
Growmax Medicare has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Growmax Medicare's Competitors and alternates
Top competitors of Growmax Medicare include AbbVie, Gilead and Amgen. Here is the list of Top 10 competitors of Growmax Medicare, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | AbbVie 2012, Chicago (United States), Public | Research-based biopharmaceutical company | $14.7B | 83/100 | |
2nd | Gilead 1987, Foster City (United States), Acquired | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | - | 81/100 | |
3rd | Amgen 1980, Thousand Oaks (United States), Public | Developer of pharmaceutical products for treating multiple diseases | - | 79/100 | |
4th |  AstraZeneca 1999, Cambridge (United Kingdom), Public | Developer of pharmaceutical medicines for oncology and various chronic diseases | - | 76/100 | |
5th | Lilly 1876, Indianapolis (United States), Public | Developer of traditional pharmaceutical medicines | - | 75/100 | |
6th |  Johnson & Johnson 1886, New Brunswick (United States), Public | Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products | - | 74/100 | |
7th | Novartis 1996, Basel (Switzerland), Acquired | R&D focused on manufacturing of drugs for multiple therapeutic areas | - | 71/100 | |
8th |  Roivant Sciences 2014, New York City (United States), Public | Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases | $1.3B | 72/100 | |
9th |  Roche 1896, Basel (Switzerland), Public | Developer of pharmaceuticals and diagnostics kits | - | 70/100 | |
10th | Genentech 1976, San Francisco (United States), Acquired | R&D company focused on manufacturing drugs for multiple therapeutic areas | $72.5M | 68/100 | |
1722nd |  Growmax Medicare 2008, India, Unfunded | Manufacturer of pharmaceutical formulations including cardiac, diabetic, and nutritional products | - | - | 16/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Growmax Medicare's competitors? Click here to see the top ones
Growmax Medicare's Investments and acquisitions
Growmax Medicare has made no investments or acquisitions yet.
Reports related to Growmax Medicare
Here is the latest report on Growmax Medicare's sector:
Are you a Founder ?
FAQs about Growmax Medicare
Explore our recently published companies
- Olse Parlor - Unfunded company
- 10sBetY - Unfunded company
- A2J Bet - Unfunded company
- MaBe - Unfunded company
- Lucky Win 379 - Unfunded company
- XLDigital - United Kingdom based, 2025 founded, Unfunded company
